Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.
Alhamadsheh, M.M., Connelly, S., Cho, A., Reixach, N., Powers, E.T., Pan, D.W., Wilson, I.A., Kelly, J.W., Graef, I.A.(2011) Sci Transl Med 3: 97ra81-97ra81
- PubMed: 21865539 
- DOI: 10.1126/scitranslmed.3002473
- Primary Citation of Related Structures:  
3P3R, 3P3S, 3P3T, 3P3U - PubMed Abstract: 
A valine-to-isoleucine mutation at position 122 of the serum protein transthyretin (TTR), found in 3 to 4% of African Americans, alters its stability, leading to amyloidogenesis and cardiomyopathy. In addition, 10 to 15% of individuals older than 65 years develop senile systemic amyloidosis and cardiac TTR deposits because of wild-type TTR amyloidogenesis ...